[Dendritic cell-based therapeutic vaccination for acute myeloid leukemia].

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Bulletin du Cancer

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1684/bdc.2012.1587PMID 22641288
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia.

  2011cited by this paper
• Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers

  2011cited by this paper
• A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co‐pulsed with WT1 peptide and zoledronate

  2011cited by this paper
• Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells

  2010cited by this paper
• Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination

  2010cited by this paper
• Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.

  2010cited by this paper
• Dendritic Cells (DCs) Can Be Successfully Generated From Leukemic Blasts in Individual Patients With AML or MDS: An Evaluation of Different Methods

  2010cited by this paper
• Dendritic Cell-Based Cancer Gene Therapy

  2009cited by this paper
• The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

  2009cited by this paper
• Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties

  2009cited by this paper
• Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

  2009cited by this paper
• Potential of dendritic cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide‐ and keyhole limpet hemocyanin‐pulsed, donor‐derived dendritic cell vaccine for acute myeloid leukemia

  2008cited by this paper
• Dendritic cell vaccines in acute leukaemia.

  2008cited by this paper
• Current approaches in dendritic cell generation and future implications for cancer immunotherapy

  2007cited by this paper
• Phase I/II study of vaccination with dendritic‐like leukaemia cells for the immunotherapy of acute myeloid leukaemia

  2006cited by this paper
• Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.

  2006cited by this paper
• Acute myeloid leukaemia.

  2006cited by this paper
• Wilms' tumour gene 1 (WT1) in human neoplasia

  2005cited by this paper
• Immunoselection of Functional CMRF-56+ Blood Dendritic Cells from Multiple Myeloma Patients for Immunotherapy

  2005cited by this paper
• Dendritic cell immunotherapy: mapping the way

  2004cited by this paper
• Immunotherapy using autologous monocyte‐derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation

  2004cited by this paper
• Treatment of Post-Transplanted, Relapsed Patients with Hematological Malignancies by Infusion of HLA-Matched, Allogeneic-Dendritic Cells (DCs) Pulsed with Irradiated Tumor Cells and Primed T Cells

  2001cited by this paper
• Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia.

  1997cited by this paper

• Immunotherapeutic Potential of m6A-Modifiers and MicroRNAs in Controlling Acute Myeloid Leukaemia

  2021cites this paper
• of the Radboud University Nijmegen

  2017cites this paper
• Correction: Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential

  2014cites this paper
• Current world literature.

  2013cites this paper
• IMMUNOTHERAPY IN LEUKAEMIA

  2012cites this paper
• Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential

  2012cites this paper
• Minimal residual disease in acute myeloid leukemia: coming of age.

  2012cites this paper